Earnings summaries and quarterly performance for Bionano Genomics.
Executive leadership at Bionano Genomics.
Board of directors at Bionano Genomics.
Research analysts who have asked questions during Bionano Genomics earnings calls.
SJ
Sung Ji Nam
Scotiabank
3 questions for BNGO
Also covers: ADPT, BDSX, CSTL +9 more
DB
Destiny Buch
Ladenburg Thalmann & Co. Inc.
1 question for BNGO
Also covers: CCLD, NBY, NNOX +1 more
JL
Joanne Lee
Maxim Group
1 question for BNGO
Also covers: ACXP, BCLI, MTNB
Mark Massaro
BTIG, LLC
1 question for BNGO
Also covers: ADPT, AKYA, BLLN +19 more
Michael Okunewitch
Maxim Group
1 question for BNGO
Also covers: BLFS, BLTE, BRTX +11 more
MO
Michael Okunowicz
Maxim Group
1 question for BNGO
Vidyun Bais
BTIG
1 question for BNGO
Also covers: AKYA, CERS, CSTL +5 more
VC
Vivian Cervantes
BTIG
1 question for BNGO
Also covers: TKNO
YC
Yi Chen
H.C. Wainwright & Co.
1 question for BNGO
Also covers: ANGO, APDN, BLFS +22 more
Recent press releases and 8-K filings for BNGO.
Bionano Genomics Reports Preliminary Q4 and Full-Year 2025 Results
BNGO
Earnings
Guidance Update
- Bionano Genomics reported preliminary total revenue for Q4 2025 in the range of $7.8 million to $8.0 million, representing a 2% to 4% decrease year-over-year.
- For the full year 2025, preliminary total revenue is expected to be between $28.4 million and $28.6 million, a 7% to 8% decrease year-over-year.
- The company sold 7,554 nanochannel array flowcells in Q4 2025 and 30,171 for the full year 2025.
- Bionano installed 9 new OGM systems in Q4 2025 and 32 for the full year, bringing the total installed base to 387 OGM systems by year-end 2025.
- As of December 31, 2025, cash, cash equivalents, available-for-sale securities, and restricted short-term investments totaled approximately $29.6 million.
Jan 12, 2026, 1:15 PM
Bionano Genomics Reports Preliminary Q4 and Full-Year 2025 Results
BNGO
Earnings
Guidance Update
- Bionano Genomics expects preliminary, unaudited total revenue for Q4 2025 to be between $7.8 million and $8.0 million, representing a 2% to 4% year-over-year decrease, and full-year 2025 revenue between $28.4 million and $28.6 million, a 7% to 8% year-over-year decrease.
- The company reported 30,171 nanochannel array flowcells sold and an installed base of 387 OGM systems at year-end 2025, compared to 371 at year-end 2024.
- As of December 31, 2025, cash, cash equivalents, available-for-sale securities, and restricted short-term investments totaled approximately $29.6 million.
- CEO Erik Holmlin highlighted 2025 as a pivotal year, noting a transformed business model, reduced cash burn, improved gross margins, and expanded adoption of optical genome mapping (OGM) solutions.
Jan 12, 2026, 1:00 PM
Bionano Genomics Reports Q3 2025 Results, Reiterates FY25 Revenue Guidance, and Raises OGM Installation Outlook
BNGO
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Bionano Genomics (BNGO) reported Q3 2025 revenue of $7.4 million, representing a 21% increase compared to Q3 2024, alongside a Non-GAAP gross margin of 46%. Non-GAAP operating expenses for the quarter were $9.7 million, a 40% reduction from Q3 2024.
- As of September 30, 2025, the company held $31.8 million in cash, cash equivalents, and available-for-sale securities, boosted by a $10 million public offering of common stock completed in September 2025.
- Operational metrics for Q3 2025 included 8,390 flowcells sold (+7% year-over-year), 7 new OGM installations (bringing the year-to-date total to 23), and an OGM installed base of 384 systems (+4% year-over-year).
- The company reiterated its full-year 2025 revenue guidance of $26 million to $30 million and initiated Q4 2025 revenue guidance of $7.5 million to $7.9 million. Furthermore, BNGO raised its FY 2025 expectation for new OGM installations to surpass 25 systems, an increase from previous guidance of 20-25 systems.
- CMS has posted a preliminary payment determination for a new Category I CPT code for OGM in constitutional genetic disorders, with a preliminary crosswalk price of $1,263.53.
Nov 13, 2025, 9:30 PM
Bionano Genomics Reports Q3 2025 Results and Reaffirms Full-Year Guidance
BNGO
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Bionano Genomics reported Q3 2025 revenue of $7.4 million, reflecting a 21% increase compared to Q3 2024, and sold a record 8,390 flow cells, up 7% year-over-year.
- The company significantly improved its non-GAAP gross margin to 46% in Q3 2025 from 26% in Q3 2024, while non-GAAP operating expenses were reduced by 40% to $9.7 million.
- Bionano reiterated its full-year 2025 revenue guidance of $26-30 million and expects Q4 2025 revenues to be in the range of $7.5-$7.9 million.
- The company ended Q3 2025 with $31.8 million in cash, cash equivalents, and available for sale securities and completed a $10 million public offering in September, extending its cash runway into the third quarter of 2026.
- A strategic shift towards driving utilization among routine users resulted in consumables and software sales growing 15% year-over-year in Q3 2025, representing 72% of the total product mix. Additionally, CMS posted a preliminary payment determination for a new OGM CPT code at $1,263.53.
Nov 13, 2025, 9:30 PM
Bionano Genomics Reports Q3 2025 Results and Updates 2025 Outlook
BNGO
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Bionano Genomics reported total revenue of $7.4 million for the third quarter ended September 30, 2025, representing a 21% increase compared to the same period in 2024.
- The company achieved a GAAP gross margin of 46% in Q3 2025, a significant improvement from (139)% in Q3 2024, and reduced operating expenses by 66% to $11.9 million.
- Net loss for Q3 2025 was $(8.5) million, a substantial improvement from $(44.2) million in Q3 2024.
- Bionano ended the third quarter of 2025 with $31.8 million in cash, cash equivalents, available-for-sale securities, and restricted short-term investments, following a public offering in September 2025 that raised $10 million in gross proceeds.
- The company reiterated its full year 2025 revenue guidance in the range of $26.0 million to $30.0 million and initiated Q4 2025 revenue guidance in the range of $7.5 million to $7.9 million.
Nov 13, 2025, 9:04 PM
Bionano Genomics Reports Q3 2025 Results and Updates 2025 Outlook
BNGO
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Bionano Genomics reported a 21% increase in total revenue to $7.4 million for Q3 2025 compared to Q3 2024, with GAAP gross margin improving to 46% from (139)% in the prior year period.
- Operating expenses were significantly reduced by 66% to $11.9 million in Q3 2025 compared to the same period in 2024.
- The company ended Q3 2025 with $31.8 million in cash, cash equivalents, available-for-sale securities, and restricted short-term investments.
- Bionano reiterated its full year 2025 revenue guidance in the range of $26.0 to $30.0 million and initiated Q4 2025 revenue guidance between $7.5 to $7.9 million.
Nov 13, 2025, 9:01 PM
Bionano Genomics Provides Update on OGM Technology and Business Strategy
BNGO
Guidance Update
New Projects/Investments
Delisting/Listing Issues
- Bionano Genomics' core technology, Optical Genome Mapping (OGM), detects large structural variations in DNA for applications including hematologic malignancies, rare diseases, and cell and gene therapy, aiming to replace traditional cytogenetic methods.
- The company offers two OGM systems: Saphyr, an entry-level model at approximately $175,000, and Stratys, a higher-throughput system with four times the annual sample throughput of Saphyr, priced around $295,000.
- OGM consumables are the primary revenue contributor and a profit driver, while software (VIA) boasts the highest gross margin, with instruments having the lowest.
- Bionano has an installed base of 378 OGM systems globally, with 150-175 systems in routine cytogenetic labs, targeting a market of 2,500 labs in focused regions and an additional 7,500 labs internationally.
- The company has shifted its strategy to efficient growth by increasing utilization at existing customer sites, maintaining flat expenses, and recently secured financing to extend its runway, addressing a prior financing overhang and a reverse stock split in Q1 2025.
Oct 15, 2025, 2:00 PM
Bionano Outlines 2025 Revenue Guidance and Strategic Shift
BNGO
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Bionano projects 2025 revenue guidance of $26 million to $30 million, with a strategic pivot towards driving utilization of high-margin OGM consumables among existing customers.
- The company has addressed key adoption hurdles, including establishing CPT codes for hematologic malignancies (2024) and constitutional genetic disorders (2025), and is the sole provider of optical genome mapping (OGM) technology.
- Bionano reported Q2 2025 software revenues of approximately $1.3 million to $1.4 million and has substantially reduced non-GAAP operating expenses from $35 million per quarter in 2023 to $8.5 million to $9 million per quarter.
- Despite a recent financing extending its runway, Bionano anticipates needing further capital to achieve cash flow breakeven.
Oct 15, 2025, 2:00 PM
Bionano Genomics Prices $10 Million Public Offering
BNGO
- Bionano Genomics, Inc. announced the pricing of a public offering on September 16, 2025, for an aggregate of 5,000,000 shares of common stock (or common stock equivalents) and accompanying Series E and Series F warrants.
- The combined public offering price was $2.00 per share (or common stock equivalent) and accompanying Series Warrants, with an exercise price of $2.00 per share for the warrants.
- The offering is expected to generate approximately $10 million in gross proceeds before deductions, with potential additional gross proceeds of approximately $20 million if the Series Warrants are fully exercised.
- The net proceeds, approximately $9.0 million, will be used for working capital and general corporate purposes.
- The offering closed on September 17, 2025.
Sep 17, 2025, 10:02 PM
Quarterly earnings call transcripts for Bionano Genomics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more